[HTML][HTML] Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono-and multispecific immunoassays
J Damoiseaux, JB Vulsteke, CW Tseng… - Autoimmunity …, 2019 - Elsevier
Idiopathic inflammatory myopathies (IIM) are a group of diseases characterized by immune-
mediated muscular lesions that may be associated with extra-muscular manifestations …
mediated muscular lesions that may be associated with extra-muscular manifestations …
Nailfold capillaroscopy in systemic lupus erythematosus: a systematic review and critical appraisal
Nailfold capillaroscopy is an easy, non-invasive technique to assess microvascular
involvement in rheumatic diseases. Multiple studies describe capillaroscopic changes in …
involvement in rheumatic diseases. Multiple studies describe capillaroscopic changes in …
Nailfold capillaroscopy and clinical applications in systemic sclerosis
V Smith, K Thevissen, AC Trombetta, C Pizzorni… - …, 2016 - Wiley Online Library
Capillary microscopy is a safe and non‐invasive tool to evaluate the morphology of the
microcirculation typically affected in SSc. Next to being paramount for the “(very) early” …
microcirculation typically affected in SSc. Next to being paramount for the “(very) early” …
Nailfold capillaroscopy for prediction of novel future severe organ involvement in systemic sclerosis
V Smith, V Riccieri, C Pizzorni, S Decuman… - The Journal of …, 2013 - jrheum.org
Objective. Assessment of associations of nailfold videocapillaroscopy (NVC) scleroderma
(systemic sclerosis; SSc)(“early,”“active,” and “late”) with novel future severe clinical …
(systemic sclerosis; SSc)(“early,”“active,” and “late”) with novel future severe clinical …
[HTML][HTML] RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients
K Venken, P Jacques, C Mortier, ME Labadia… - Nature …, 2019 - nature.com
Abstract Dysregulated IL-23/IL-17 responses have been linked to psoriatic arthritis and other
forms of spondyloarthritides (SpA). RORγt, the key Thelper17 (Th17) cell transcriptional …
forms of spondyloarthritides (SpA). RORγt, the key Thelper17 (Th17) cell transcriptional …
Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement
V Smith, Y Piette, JT Van Praet, S Decuman… - The Journal of …, 2013 - jrheum.org
Objective. To study safety and potential efficacy of a 2-treatment course (month 0/6) with
rituximab (RTX) in early diffuse systemic sclerosis (dcSSc). Methods. Two years' followup …
rituximab (RTX) in early diffuse systemic sclerosis (dcSSc). Methods. Two years' followup …
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a …
Background Patients with primary systemic vasculitis or polymyalgia rheumatica might be at
a high risk for poor COVID-19 outcomes due to the treatments used, the potential organ …
a high risk for poor COVID-19 outcomes due to the treatments used, the potential organ …
Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort
E Vandecasteele, B Drieghe, K Melsens… - European …, 2017 - Eur Respiratory Soc
Screening for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) improves
outcomes. The DETECT screening algorithm is recommended in a high-risk SSc subgroup …
outcomes. The DETECT screening algorithm is recommended in a high-risk SSc subgroup …
Is laser speckle contrast analysis (LASCA) the new kid on the block in systemic sclerosis? A systematic literature review and pilot study to evaluate reliability of LASCA …
Objectives A reliable tool to evaluate flow is paramount in systemic sclerosis (SSc). We
describe herein on the one hand a systematic literature review on the reliability of laser …
describe herein on the one hand a systematic literature review on the reliability of laser …
Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis
K Melsens, E Vandecasteele, E Deschepper… - Acta Clinica …, 2018 - Taylor & Francis
Objectives: Following results in open-label studies of rituximab in patients with systemic
sclerosis, a Belgian three-centre initiative was launched to explore safety and efficacy of …
sclerosis, a Belgian three-centre initiative was launched to explore safety and efficacy of …